Eli Lilly (LLY) shares fell almost 4% in recent trading Monday after the Trump administration decided to table a plan allowing Medicare to pay for anti-obesity medications, which would have granted more people access to the company's weight-loss drug Zepbound.
The Centers for Medicare & Medicaid Services said Friday it was not finalizing the provision in the proposed rule at this time, but may address it in the future.
A Lilly spokesperson said Medicare's decision was not the best interpretation of the Part D Coverage provision of the rule and will impacts the access to obesity treatment.
"We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind," the spokesperson said.
Price: 709.32, Change: -28.89, Percent Change: -3.91
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。